Back to Search
Start Over
Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth.
- Source :
-
Oncotarget [Oncotarget] 2015 Sep 08; Vol. 6 (26), pp. 22126-38. - Publication Year :
- 2015
-
Abstract
- Naked cuticle homolog 2 (NKD2) has been reported to antagonize Wnt signaling in zebrafish, mouse and mammals. The aim of this study is to investigate the epigenetic changes and mechanisms of NKD2 in human breast cancer development. Six breast cancer cell lines (MCF-7, ZR75-1, MDA-MB-468, MDA-MB-231, T47D and BT474) and 68 cases of primary human breast cancer were studied using methylation specific PCR, immunohistochemistry, western blot, flow cytometry techniques and a xenograft mouse model. The expression of NKD1 and NKD2 was regulated by promoter region methylation in breast cancer cells. No NKD1 methylation was found in primary human breast cancer. NKD2 was methylated in 51.4% (35/68) of human primary breast cancer samples. NKD2 methylation was significantly associated with reduction of NKD2 expression, and tumor stage (p < 0.05). NKD2 suppressed breast cancer cell proliferation both in vitro and in vivo. NKD2 induced G1/S arrest and inhibited Wnt signaling in breast cancer cells. In conclusion, NKD2 is frequently methylated in human breast cancer, and the expression of NKD2 is regulated by promoter region methylation. NKD2 suppresses breast cancer proliferation by inhibiting Wnt signaling.
- Subjects :
- Adaptor Proteins, Signal Transducing
Animals
Breast Neoplasms pathology
Calcium-Binding Proteins
Cell Growth Processes genetics
Cell Line, Tumor
DNA Methylation
Female
Gene Silencing
Heterografts
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
Promoter Regions, Genetic
Breast Neoplasms genetics
Carrier Proteins genetics
Wnt Signaling Pathway genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1949-2553
- Volume :
- 6
- Issue :
- 26
- Database :
- MEDLINE
- Journal :
- Oncotarget
- Publication Type :
- Academic Journal
- Accession number :
- 26124080
- Full Text :
- https://doi.org/10.18632/oncotarget.4244